secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2021-10-28T23:59:59+00:00
Accession:  0001104659-21-130675
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q3 sales $13.2B (+20% YoY); raises FY2021 guidance; to acquire Acceleron for $11.5B
--------------------------------------------------------------------------------

- Q3 GAAP EPS $1.80, Non-GAAP EPS $1.75; sales $13.2B (+20% YoY, +19% ex-FX).
- Keytruda sales $4.5B (+22%); Gardasil $2.0B (+68%); Animal Health $1.4B (+16%).
- Raises FY2021 revenue guidance to $47.4B–$47.9B; Non-GAAP EPS to $5.65–$5.70.
- Agreement to acquire Acceleron Pharma for $180/share (~$11.5B); expected close Q4 2021.
- Submitted EUA for molnupiravir (oral COVID-19 treatment) based on positive Phase 3 data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465921130675/0001104659-21-130675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465921130675/tm2131077d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-130675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer